{
    "clinical_study": {
        "@rank": "102385", 
        "arm_group": {
            "arm_group_label": "Pegloticase", 
            "arm_group_type": "Experimental", 
            "description": "Pegloticase 8 mg single intraveneous dose"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1 single dose study conducted to evaluate the PK and PD of pegloticase\n      administered to hemodialysis patients.\n\n      A single dose of pegloticase will be administered intravenously to male or female\n      hemodialysis patients (N = 12) starting 3 hour prior to dialysis.\n\n      The study consists of a Screening Period, a Treatment Period, and Follow up Period."
        }, 
        "brief_title": "Study to Assess Pegloticase (KRYSTEXXA\u00ae) in Patients on Hemodialysis", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Kidney Disease Stage 5", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "End stage renal disease (ESRD) patients that require hemodialysis typically undergo\n      hemodialysis treatment 3 times per week. As such, medications can be dialyzed off, reducing\n      their clinical effectiveness; this study is being conducted to understand how dialysis\n      affects the pharmacokinetics (PK) and pharmacodynamics (PD) of pegloticase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18 and 75 years of age, inclusive\n\n          2. Agrees to employ best possible methods to abstain from becoming pregnant or\n             impregnating another.\n\n          3. Stage V chronic kidney patients with minimal or no residual renal function receiving\n             hemodialysis and stable on hemodialysis (3x week)\n\n          4. BMI = 18.5 kg/m2 to < 45 kg/m2\n\n        Exclusion Criteria:\n\n          1. Any surgical or medical condition that may interfere with drug absorption,\n             distribution, metabolism, or excretion, or any other condition that may place the\n             subject at risk\n\n               1. Glucose-6-phosphate dehydrogenase (G6PD) deficiency\n\n               2. Uncontrolled congestive heart failure\n\n               3. Refractory chronic gout\n\n          2. History of drug and/or alcohol abuse within 6 months prior to screening\n\n          3. History of or current clinically significant mental disorder or an antagonistic\n             personality that compromises the validity of the informed consent\n\n          4. Donation of blood or plasma within 30 days prior to dosing\n\n          5. History of or current hepatitis, or carriers of hepatitis B surface antigen (HbsAg)\n             and/or hepatitis C antibodies (anti-HC).\n\n          6. Use of an investigational drug or product, within 30 days\n\n          7. History of clinically significant drug allergies or sensitivities\n\n          8. Females with a positive pregnancy test or who are breast feeding at Screening or plan\n             to breast feed within 30 days of dosing\n\n          9. A baseline QTc interval \u2265 490 milliseconds for males and \u2265 510 milliseconds for\n             females\n\n         10. Is unable to refrain from alcohol\n\n         11. Has taken any prescription or over the counter medication within 7 days prior to\n             treatment day that, in the opinion of the Investigator, could be expected to confound\n             the PK or metabolism of the study drug\n\n         12. Has taken the following herbal agents or nutraceuticals within 7 days prior to\n             Screening: chapparal, comfrey, germander, gin bu huan, kava, pennyroyal, skullcap,\n             St. John's Wort, or valerian\n\n         13. Has poorly controlled malignant hypertension (systolic blood pressure [SBP] > 200 mm\n             Hg and/or diastolic blood pressure [DBP] > 120 mm Hg,\n\n         14. Concurrent use of urate-lowering drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739660", 
            "org_study_id": "M0403", 
            "secondary_id": "10122"
        }, 
        "intervention": {
            "arm_group_label": "Pegloticase", 
            "description": "a single 8 mg iv (in the vein) dose before hemodialysis session", 
            "intervention_name": "Pegloticase", 
            "intervention_type": "Drug", 
            "other_name": "KRYSTEXXA"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Kidney Disease Stage 5", 
            "Hemodialysis", 
            "pegloticase"
        ], 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55404"
                }, 
                "name": "Davita Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Single Site, Open-Label Study to Assess the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pegloticase (KRYSTEXXA\u00ae) in Patients on Hemodialysis", 
        "overall_official": {
            "affiliation": "Davita Clinical Research", 
            "last_name": "Harry Alcorn, Pharm D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "\u2022 To evaluate the pharmacokinetics (PK) of pegloticase after a single-dose administration to hemodialysis patients when administered starting 3 hours before dialysis", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739660"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "\u2022 To evaluate the pharmacodynamics (PD) of pegloticase and SUA, before and after hemodialysis sessions", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "source": "Savient Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Savient Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}